Redeye provides its comment on Mendus’ Q3 2025 report. We believe several upcoming clinical readouts in 2026e could spark partner interest and reinvigorate sentiment around the share. We believe Mendus will likely need to secure continued financing until our projected licensing deal in late 2026e.
LÄS MER
